按积极达标治疗方案治疗的早期类风湿关节炎患者持续缓解的预测因素
研究纳入222例症状持续时间小于2年的未使用过改善病情抗风湿药的早期类风湿关节炎患者,按预设方案治疗。118例(53%)达到持续DAS缓解。基线Ritchie关节压痛指数越高,持续缓解概率越低(OR=0.90/单位)。基线症状持续时间短预测持续Boolean和SDAI缓解。
要点
- 基线Ritchie关节压痛指数每增加1单位,持续DAS缓解的OR=0.90(95%CI:0.86,0.94)。
- 基线症状持续时间短预测持续Boolean缓解和持续SDAI缓解。
- 222例中118例(53%)达到持续DAS缓解,53例(24%)达到持续Boolean缓解。
核心结论
- 基线关节压痛评分较高在所有缓解定义下均一致降低达到持续缓解的可能性。
- 研究结果支持持续缓解是早期类风湿关节炎可达到的目标,尤其是在症状持续时间3个月内开始使用改善病情抗风湿药时。
研究设计与样本
- 研究纳入222例未使用过改善病情抗风湿药、症状持续时间小于2年的早期类风湿关节炎患者,按预设算法治疗。
- 预设算法允许根据已知的不良预后危险因素调整治疗。
- 采用多变量逻辑回归分析基线预测因素与16-24个月持续DAS缓解及次要持续缓解结局的关系。
主要发现
- 222例患者中118例(53%)达到持续DAS缓解,53例(24%)达到持续ACR/EULAR Boolean缓解,73例(33%)达到持续SDAI缓解。
- 基线Ritchie关节压痛指数较高是持续DAS缓解的负性预测因素(OR=0.90/单位,95%CI:0.86,0.94)。
- 基线Ritchie关节压痛指数较高是持续ACR/EULAR Boolean缓解的负性预测因素(OR=0.92,95%CI:0.86,0.98)。
- 基线Ritchie关节压痛指数较高是持续SDAI缓解的负性预测因素(OR=0.94,95%CI:0.90,1.00)。
- 基线症状持续时间短预测持续Boolean缓解和持续SDAI缓解。
关键数值与推荐
- 持续DAS缓解:16-24个月期间达到DAS缓解。
- 持续ACR/EULAR Boolean缓解:16-24个月期间达到ACR/EULAR Boolean缓解。
- 持续SDAI缓解:16-24个月期间达到SDAI缓解。
- 其他持续缓解结局包括无肿胀关节以及DAS缓解、无肿胀关节和无影像学进展的复合结局。
临床怎么用
- 原文未据此给出推荐。
局限性
- 其他已识别的预测因素在不同结局间不一致。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To study prognostic factors for achievement of sustained remission in early RA patients receiving semi-personalized tight controlled treatment, and to assess the consistency of potential predictors across definitions of sustained remission. METHODS: DMARD-naïve early RA patients with symptom duration <2 years were treated according to a pre-defined algorithm within the Aiming for Remission in rheumatoid arthritis: a randomised trial examining the benefit of ultrasound in a Clinical TIght Control regimen trial. The algorithm allowed treatment adjustments based on established risk factors for a worse outcome. Multivariate logistic regression was used to examine baseline predictors of achieving sustained DAS remission at 16-24 months, and to assess predictors of secondary remission outcomes (all sustained 16-24 months): ACR/EULAR Boolean, Simplified Disease Activity Index (SDAI), no swollen joints and a composite outcome of DAS remission, no swollen joints and no radiographic progression. RESULTS: Of 222 patients, 118 (53%) reached sustained DAS remission, while 53 (24%) reached sustained ACR/EULAR Boolean and 73 (33%) sustained SDAI remission. More joint tenderness, assessed by Ritchie Articular Index, was a negative predictor of reaching sustained DAS remission (odds ratio (OR) = 0.90/U, 95% CI: 0.86, 0.94), sustained ACR/EULAR Boolean remission (OR = 0.92, 95% CI: 0.86, 0.98), sustained SDAI remission (OR = 0.94, 95% CI: 0.90, 1.00) as well as the two alternative definitions of sustained remission. Short symptom duration at baseline predicted sustained Boolean and SDAI remission. Other identified predictors were inconsistent across outcomes. CONCLUSION: A higher tender joint score at baseline consistently reduced the chance of reaching sustained remission across all definitions. Our results support sustained remission as an achievable goal in early RA, especially when initiating DMARDs within 3 months symptom duration. TRIAL REGISTRATION: ClinicalTrials.gov, http://clinicaltrials.gov, NCT01205854.
引用
- Paulshus Sundlisæter N, Olsen IC, Aga AB, et al. Predictors of sustained remission in patients with early rheumatoid arthritis treated according to an aggressive treat-to-target protocol. Rheumatology (Oxford). 2018. PMID: 30053199. doi:10.1093/rheumatology/key202
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。